Nonalcoholic Fatty Liver Disease
Conditions
Interventions
To apply a tape to collect sebum on the site of collection (forehead, neck, precordium) for long times.
Sponsors
Chugai Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Common items: The contents of the present research have been sufficiently explained, and their written voluntary consent has been obtained. - >= 18 to =< 70 years For healthy adult volunteers: - without fatty liver - Not to have any disease requiring outpatient visits and am healthy. - Normal renal function For patients with nonalcoholic fatty liver disease: - diagnosed with hepatic steatosis or steatohepatitis in the past - The subject has fatty deposits in the liver confirmed by abdominal ultrasound performed within 6 months prior to the day of sebum collection.
Exclusion criteria
Exclusion criteria: Common items: - Ethanol hypersensitivity - Persons who have experienced skin irritation by adhesive tapes - Alcohol consumption >= 30 g/day (males) or >= 20 g/day (females). - Taking supplements such as vitamin and Minerals within 1 week of the day of sample collection (However, drugs including vitamins and minerals that are continuously used as therapeutic drugs for diseases are excluded.) - Prior surgery of the pancreatic and gallbladder system - Researchers involved in this research - the doctor judges it difficult for you to participate For healthy volunteers: - Hepatobiliary disease and medical history - Abdominal echo shows fatty liver For patients with nonalcoholic fatty liver disease: - Moderate or severe renal impairment (eGFR < 60 mL/min/1.73 m^2) - other hepatobiliary disorders are suspected; alcoholic liver disease, autoimmune liver disease, cholangitis, Alpha-1 antitrypsin deficiency, such as Wilson disease, Drug-induced liver injury, viral liver diseases such as HBV/HCV, cirrhosis, liver cancer, previous intravenous drug administration within 1 month before sample collection, Thyroid and adrenal disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Selection of biomarker candidates related with liver fibrosis by metabolome analysis in sebum components | — |
Countries
Japan
Contacts
Public ContactChugai Pharmaceutical Co., Ltd. Clinical trials information
Chugai Pharmaceutical Co., Ltd. Clinical Strategy and Resource Management Dept.
Outcome results
None listed